Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

488 questions · 501 findings · 191 reviews

No studies found 126 · 25.1%GRADE not reported 124 · 24.8%Very low 104 · 20.8%Low 89 · 17.8%Moderate 49 · 9.8%High 9 · 1.8%

Sulodexide (heparin plus dermatan sulphate chains) vs prednisone

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review

Colchicine (0.5 mg per day for 3 months) vs prednisolone

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Adverse event: tremor · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: tremor compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Adverse effects: headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: headache compared with placebo (very low certainty).

1 finding from 1 review

Valaciclovir (short‐term) vs placebo

Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis

Valaciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).

1 finding from 1 review

Topical aciclovir (short‐term) vs placebo

Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis

Topical aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (low certainty).

1 finding from 1 review